|
Nasdaq:QGENF
Qiagen
N.V. is a provider of enabling technologies and products for the separation
and purification of nucleic acids
QIAGEN Signs Agreement for
the Acquisition of eGene
Strategic Transaction adds
Capillary Sample Separation Technology Targeting Molecular Diagnostics
and Other Applications
VENLO, The Netherlands, April
12, 2007 - QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA),
the world's leading provider of sample and assay technologies for research
in life sciences, applied testing and molecular diagnostics, today announced,
that its subsidiary QIAGEN North American Holdings, Inc. has signed a definitive
merger agreement with eGene, Inc. (Nasdaq OTC/BB: EGEI) pursuant to which
eGene would become a fully owned subsidiary of QIAGEN North American Holdings,
Inc. eGene is an early-stage company located in Irvine, California, that
has developed and is commercializing a patented sample separation and analysis
technology based on capillary electrophoresis. The transaction has been
approved by the boards of directors of both companies and is expected to
close, subject to regulatory and stockholder approvals and customary closing
conditions in the third quarter of 2007.
eGene has developed a multi-channel
sample separation and analysis technology for nucleic acids that includes
an affordable and robust instrument, software analysis package, and a selection
of consumable cartridges specifically designed for specific high value
applications in the molecular diagnostic and research markets. The HDA-GT12™
Genetic Analyzer is a revolutionary multi-capillary system which incorporates
many capabilities into one easy to use platform, integrating automatic
sample loading, separation, and data analysis.
|
